ARVs / HIVs

Aurobindo Pharma aims to achieve the goals of wider access to HIV treatment, care and support, halting and reversing the spread of HIV and contributing to the achievement of the Millennium Development goals set by UNAIDS by 2015.

To ensure that treatment is available within reach in developing countries, Aurobindo Pharma has ensured expansion of its global footprint in providing quality medicines at affordable prices. With continuous quality improvement efforts, we have reduced the cost of treatment to less than 1/10th of the innovators products, thereby treating over seven million patients in some way.! Of this, an estimated 4,20,000 to 4,60,000 were children.

The figure above represents a 16-fold increase in the number of people receiving anti-retroviral therapy in developing countries between 2003 and 2010. This tremendous increase in our reach over the years is the result of actively working to acclimatize and improve our reach in many countries, and incorporating feedback from many different stake holders.

In the next few years the number of people in need of treatment is expected to grow to 30 million. Nearly all these patients belong to the underdeveloped countries for which cost effective drugs produced at Aurobindo will be a boon. Our low-cost generic versions of more than 43 anti-retroviral products cater to more than 100 countries across various continents.